MedTrace Logo

Population Pharmacokinetics of Lassila Tazobactam in Patients After Aortic Dissection

NCT05349305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-04-27

No results posted yet for this study

Summary

The individualized drug use research on optimizing piperacillin tazobactam for CRRT of hospital-acquired pulmonary infection after cardiopulmonary bypass is still in the initial stage at home and abroad, lacking systematic research data. With the help of the population pharmacokinetic model, it can help clinicians to formulate individualized drug administration plans for such patients and provide methodological and data support for precise treatment. The rational use of piperacillin tazobactam will play an important role in reducing the use of carbapenems and curbing the occurrence of drug resistance.

Conditions

  • Aortic Dissection
  • Lung Infection

Interventions

DRUG

continuous renal replacement therapy

continuous renal replacement therapy

Sponsors & Collaborators

  • The Second Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2023-12-31
Completion
2024-07-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349305 on ClinicalTrials.gov